{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FGEJ&page=2", "query": { "condition": "Gastric/GEJ", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FGEJ&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:50:48.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04208958", "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Melanoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "VE800", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Vancomycin Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Vedanta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2020-01-23", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208958" }, { "nct_id": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumors", "Colorectal Cancer (CRC)", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Renal Cell Carcinoma (RCC)", "Bladder Cancer", "UC (Urothelial Cancer)", "Mesothelioma" ], "interventions": [ { "name": "INCB001158", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2016-09-14", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 13, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903914" }, { "nct_id": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Sonesitatug vedotin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Zolbetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2130, "start_date": "2026-02-03", "completion_date": "2031-10-27", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 77, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 66 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07431281" }, { "nct_id": "NCT03662659", "title": "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Cancer of the Stomach", "Esophagogastric Junction" ], "interventions": [ { "name": "BMS-986213", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "XELOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "SOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2018-10-16", "completion_date": "2024-01-18", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 13, "location_summary": "Clovis, California • Duarte, California • La Jolla, California + 10 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03662659" }, { "nct_id": "NCT07454642", "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vulvar Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Small Cell Carcinoma of Lung", "Colorectal Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "AVA6103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2026-03-31", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Irving", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454642" }, { "nct_id": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "ramucirumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tucatinib placebo", "type": "OTHER" }, { "name": "trastuzumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04499924" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT05128487", "title": "A Study of NDI 1150-101 in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Renal Cell Carcinoma (Kidney Cancer)", "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "NDI-101150", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Saturn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-11-05", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocala", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05128487" }, { "nct_id": "NCT04032704", "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Non-small Cell Lung Cancer, Squamous", "Non-small Cell Lung Cancer, Non-squamous", "Head and Neck Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Prostate Cancer", "Melanoma" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2019-10-09", "completion_date": "2023-11-28", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 27, "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032704" }, { "nct_id": "NCT04847466", "title": "Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Junction (GEJ) Cancers", "Advanced HNSCC" ], "interventions": [ { "name": "N-803", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2021-12-14", "completion_date": "2026-01-06", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T17:50:48.504Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847466" } ] }